Achieving launch excellence in orphan medicines

New rare disease treatments face a complex market access landscape that presents fundamental challenges for pharmaceutical companies seeking to achieve launch excellence.

Each rare disease might only affect a small percentage of the population, but orphan medicines are growing in interest and importance for pharmaceutical companies, increasing the pressure to make each product launch as successful as possible.

A new frontier of challenge faces Orphan Medicines companies as the gap between Orphan Medicines and mainstream specialty products narrows. 

To assess the market access environment for orphan medicines, and launch excellence strategies that manufacturers can employ, a recent IQVIA report examined some of the challenges that pharma companies face.